关键性3期诊疗一体化试验:未来适应症展望
本综述汇总了正在进行的多个放射性药物治疗(RPT)3期随机试验,涵盖前列腺癌的PSMA靶向治疗(PSMAcTION、STAMPEDE2、PSMA-DC、PSMAddition)及神经内分泌肿瘤的生长抑素受体靶向治疗(NETTER-3、ACTION-1、COMPOSE)。这些试验由产业投资增加驱动,融合核医学影像与给药流程及肿瘤学标准治疗与终点定义,有望拓展RPT适应症并变革未来癌症诊疗。
要点
- PSMAcTION、STAMPEDE2、PSMA-DC、PSMAddition等3期试验聚焦前列腺癌PSMA靶向RPT。
- NETTER-3、ACTION-1、COMPOSE评估生长抑素受体靶向RPT用于神经内分泌肿瘤。
- 3期RPT试验融合核医学影像给药与肿瘤学标准终点,有望拓展适应症。
核心结论
- 正在进行的RPT 3期试验有望在未来数年提供改变实践的循证证据,拓展放射性药物治疗的应用。
研究设计与样本
- 本综述覆盖旨在拓展RPT应用的关键性3期随机试验,涉及前列腺癌与神经内分泌肿瘤等适应症。
主要发现
- PSMAcTION、STAMPEDE2、PSMA-DC、PSMAddition聚焦前列腺癌患者的PSMA靶向治疗。
- NETTER-3、ACTION-1、COMPOSE评估生长抑素受体靶向放射性药物用于神经内分泌肿瘤患者。
- 3期注册试验的扩展由产业投资增加所驱动。
- 正在进行的RPT 3期试验兼具核医学影像与给药流程及肿瘤学标准治疗与终点定义的双重特征。
临床怎么用
- 核医学医师应关注上述3期RPT试验的适应症拓展与影像引导RPT的整合趋势。
局限性
- 综述指出RPT 3期试验中核医学与肿瘤学标准整合存在挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are several ongoing phase 3 randomized trials involving radiopharmaceutical therapies (RPTs), which are expected to provide practice-changing evidence in the coming years. This review covers ongoing pivotal phase 3 trials designed to expand applications for RPTs. Trials such as PSMAcTION, STAMPEDE2, PSMA-DC, and PSMAddition focus on prostate-specific membrane antigen-directed treatments for patients with prostate cancer. NETTER-3, ACTION-1, and COMPOSE evaluate somatostatin receptor-targeted radiopharmaceuticals in individuals with neuroendocrine neoplasms. Expansion of phase 3 registration trials has been driven by increased industry investment. Ongoing RPT phase 3 trials serve as hybrids, merging nuclear medicine procedures for imaging and drug application with oncology-driven standards of care and endpoint definitions. Despite the challenges associated with this integration, phase 3 RPT trials present an opportunity to revolutionize future cancer care by introducing and expanding the use of image-guided RPT.
引用
- Fendler WP, Hofman MS, Kersting D, et al. Pivotal Phase 3 Theranostic Trials: Future Indications. J Nucl Med. 2026. PMID: 42728102. doi:10.2967/jnumed.125.269486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。